Status:
COMPLETED
MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
Lead Sponsor:
Medical University of Vienna
Collaborating Sponsors:
St. Vincent Hospital, Vienna
Conditions:
Postmenopausal Osteoporosis
Diabetes Type 2
Eligibility:
FEMALE
60-80 years
Phase:
PHASE4
Brief Summary
The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.
Detailed Description
Primarily the influence of the therapeutic treatment on the microRNA concentration in the serum (treatment-response) and the relation between microRNA serum levels and changes of the bone mineral dens...
Eligibility Criteria
Inclusion
- Postmenopausal women
- Age 60-80 years
- T-score according to DXA: \<-2.5
- indication for osteoporosis therapy according to international guidelines
Exclusion
- Diabetes mellitus type 1
- renal insufficiency III-V °
- Cirrhosis hepatis (Child B or higher)
- Chronic alcohol abuse
- rheumatic disease (RA, SpA, SLE)
- Malignancies (\<5 years)
- Eating Disorder (anorexia nervosa, bulimia)
- bone-specific pretreatment (DMAB, TPTD, strontium ranelate, SERMs) Bisphosphonate treatment is allowed
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03472846
Start Date
March 1 2017
End Date
September 30 2022
Last Update
January 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Vienna; St. Vincent Hospital
Vienna, Austria, 1060